July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
8 citations
,
March 2023 in “PubMed” JAK inhibitors show promise in treating difficult skin diseases.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
15 citations
,
January 2014 in “Anais Brasileiros de Dermatologia” Lupus treatment requires a combination of drugs and therapies, with research needed for new options.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The serum with microneedling effectively treats alopecia areata by enhancing drug delivery and is safe and patient-friendly.
24 citations
,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
December 2022 in “Zenodo (CERN European Organization for Nuclear Research)” Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.
March 2005 in “Journal of the American Academy of Dermatology” Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
25 citations
,
March 2017 in “International Journal of Dermatology” Ruxolitinib effectively and safely regrows hair in alopecia patients.
January 2019 in “Springer eBooks” Modified HDL can better deliver drugs and genes, potentially improving treatments and reducing side effects.
26 citations
,
March 2015 in “American journal of clinical dermatology” Topical clobetasol is recommended over mycophenolate mofetil for treating Lichen Planopilaris due to better safety and patient satisfaction.
February 2025 in “medRxiv (Cold Spring Harbor Laboratory)” GLP-1 agonists may increase the risk of hair loss.
2 citations
,
March 2022 in “Dermatologic Therapy” Latanoprost 0.005% solution safely increases hair density and regrowth in scalp alopecia areata.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
January 2024 in “Acta dermato-venereologica” November 2025 in “Journal of Dermatological Treatment” Dexamethasone oral mini-pulse therapy effectively treats severe alopecia areata when JAK inhibitors can't be used.
January 2008 in “Zhonghua linchuang mianyi he biantai fanying zazhi” The treatment with Shunyou and prednisone is effective and safe for lupus nephritis.
2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
97 citations
,
December 2011 in “New England Journal of Medicine” The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
May 2023 in “Journal of managed care & specialty pharmacy” Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
6 citations
,
September 2014 in “Cutaneous and ocular toxicology” Acitretin can cause eyebrow and eyelash hair loss.
August 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
1 citations
,
January 2005 in “Side effects of drugs annual” The document concluded that various dermatological treatments have different effectiveness and side effects, with some causing irritation, allergic reactions, or systemic effects.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
2 citations
,
January 2022 in “JAAD Case Reports” The rash resolved after stopping ponatinib.